Key Points
- Personalis CEO Christopher Hall sold 80,091 shares on May 29 in a pre-arranged Rule 10b5-1 transaction, generating about $882,603 and reducing his stake by 25.34%.
- The company recently reported mixed quarterly results: EPS of -$0.29 missed expectations, while revenue of $15.47 million came in above estimates.
- Analyst sentiment remains moderately positive overall, with a consensus target price of $11.00 and a mix of Buy, Hold, and Sell ratings across firms.
Personalis, Inc. (NASDAQ:PSNL - Get Free Report) CEO Christopher Hall sold 19,909 shares of the firm's stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $11.02, for a total value of $219,397.18. Following the sale, the chief executive officer directly owned 235,986 shares of the company's stock, valued at $2,600,565.72. This trade represents a 7.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Personalis Price Performance
PSNL opened at $11.40 on Friday. Personalis, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $11.85. The business has a 50-day moving average of $6.86 and a 200-day moving average of $8.10. The company has a market capitalization of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96.
Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million for the quarter, compared to analysts' expectations of $14.49 million. On average, equities research analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on PSNL shares. Morgan Stanley cut their price target on Personalis from $10.00 to $9.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 12th. Needham & Company LLC raised their price objective on Personalis from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, February 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen raised Personalis from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, BTIG Research cut their price objective on Personalis from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Personalis has an average rating of "Moderate Buy" and an average target price of $11.00.
Get Our Latest Stock Report on Personalis
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in Personalis by 85.4% in the 1st quarter. Bank of America Corp DE now owns 111,306 shares of the company's stock worth $709,000 after buying an additional 51,273 shares during the period. Janus Henderson Group PLC bought a new position in Personalis in the 1st quarter worth approximately $192,000. ADAR1 Capital Management LLC bought a new position in Personalis in the 1st quarter worth approximately $159,000. Sei Investments Co. increased its position in Personalis by 148.3% in the 1st quarter. Sei Investments Co. now owns 139,046 shares of the company's stock worth $886,000 after buying an additional 83,040 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Personalis by 8.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company's stock worth $6,791,000 after buying an additional 83,074 shares during the period. 61.91% of the stock is owned by institutional investors.
Personalis Company Profile
(
Get Free Report)
Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.
In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
